Introduction
Modern R&D organizations, from global pharmaceutical giants to specialized biotech and CDMOs, invest vast time, talent, and capital in developing breakthrough drugs, cell and gene therapies, vaccines, and new ingredients. But every promising asset, from a biological sample to a finished stability batch, is only as valuable as its integrity and viability.
Behind every vial, slide, or test batch lies a critical truth: storage is not passive. If a sample fails while in storage, the research timeline fails with it. It is easy to focus on the volume of material archived — thousands to millions of samples stored across global networks — while overlooking whether each unit is genuinely protected, tracked, and accessible when needed.
Mid-tier and large companies with multiple sites, CROs, and CDMOs feel this risk most keenly. A single oversight can delay trials, force retesting, breach regulatory conditions, and ultimately affect patient access to therapies. The stakes are high: industry data suggests temperature excursions alone, cost global pharma nearly $35 billion annually in losses (1). The solution starts with asking: are your samples just stored, or are they truly safeguarded for the future (see Figure 1)?
The hidden risks in R&D storage
At its core, sample storage must preserve viability, not just maintain presence. Many companies learn this lesson the hard way: freezers age, power supplies falter, temperature alarms go unnoticed. Even robust systems can fail if staff assume a “set-and-forget” mentality.
A worrying industry statistic highlights the scale of the challenge: 4% of pharma shipments experience temperature excursions, and 1 in 10 pharmaceutical shipments sustains damage during transit (2). This means a significant fraction of stored or transported samples may fail quality checks when they reach the bench. The costs are not limited to wasted batches; they include hours of duplicated lab work, lost patient samples, delayed approvals, and reputational damage if studies fail inspections.
Practical steps to address this risk start with routine checks, validated equipment maintenance, and clear SOPs for temperature monitoring, alarm escalation, and corrective actions. Organizations should regularly revisit whether their storage infrastructure matches the scale and type of samples they now manage; not what they managed five or ten years ago.
Regulatory complexity: getting storage right globally
One of the biggest drivers of storage risk is regulatory diversity. Any company storing samples for clinical or commercial use must comply with overlapping international sample storage compliance standards: International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Q1A, ICH Q1B and ICH Q5C (stability testing), International Organization for Standardization (ISO) quality management standards, current good manufacturing practices (cGMP) and region-specific guidelines. Requirements often vary by product class — biologics, small molecules, vaccines — and by intended use.
In practical terms, this means an R&D director or operations team must ensure each sample storage equipment validation procedure meets regulatory compliance standards and the condition of samples in storage are validated for their full lifespan, sometimes years. This includes verifying backup power systems, ensuring humidity control is appropriate for local climate conditions, and maintaining complete, inspection-ready records of environmental monitoring.
The US Food and Drug Administration (FDA)-adopted ICH guidelines reinforce these expectations: ICH Q1A(R2) for small molecule stability and ICH Q5C for biologics. Both require stability studies to be conducted under qualified, validated, and continuously monitored storage conditions to ensure integrity across the sample lifecycle. Both guidelines, together with GMP requirements, also highlight the importance of contingency systems to protect against temperature excursions caused by power failures or equipment malfunctions (3,4). The importance of robust storage infrastructure is further underscored by FDA inspection data: in 2023, equipment-related issues (Subpart D) accounted for approximately 16.4% of all Form 483 observations. While facilities-related issues (Subpart B) made up 12.7% (5), illustrating how gaps in equipment validation, service, or environmental controls remain leading causes of regulatory non-compliance.
Environmental context matters too. For instance, storage in tropical regions may require higher humidity tolerance, while long-term biologics preservation often depends on sub-zero freezers or liquid nitrogen tanks with redundant fill alarms. Smaller organizations may lack the infrastructure or expertise to manage these nuances effectively, and compliance risks are amplified when sample storage is distributed across multiple locations or outsourced to third parties without standardized oversight.
Best practice tip: Match sample requirements to the right controlled-temperature environment and have validated quality processes in place.
The cold chain and transport challenge
But storage is only half the story — the other half is transport. For many companies, the same samples that sit stable in ultra-low freezers must move globally between clinical sites, testing labs, or manufacturing partners. Every shipment adds risk: poor packaging, delays at customs, or temperature excursions in transit can undo months of carefully controlled storage.
Cold chain logistics alone can account for up to 20% of a pharmaceutical company’s total supply chain costs, according to Grand View Research (6). As product portfolios expand, with more biologics, personalized medicines, and global clinical trials, logistics teams quickly reach capacity managing multiple couriers, temperature ranges, and chain-of-custody requirements.
Modern best practice includes smart tracking inside shipping containers to log temperatures in real time and trigger alerts if thresholds are breached. Customs documentation must meet country-specific import rules, especially for regulated biological samples. A robust cold chain process also defines who monitors the chain of custody, who takes action on any deviation, and how returns or replacements are handled quickly to prevent patient or trial delays.
Industry analyses show that outsourcing temperature-controlled logistics to specialist providers can lower total supply chain costs while also improving compliance and end-to-end visibility. This doesn’t mean outsourcing everything, but it does explain why many organizations now use hybrid models, combining in-house oversight with external specialist logistics partners for critical cold chain legs.
Disaster recovery: the cost of not planning
What happens if a storage freezer fails overnight? Or if a facility faces an unexpected power outage or flood? These are not rare hypotheticals; they are day-to-day realities. The truth is that most disruptions are internal, not caused by dramatic natural disasters. A stuck generator, a tripped alarm, or a backup system that is not serviced can trigger a chain reaction.
Consider one large CRO: its fleet of ten-year-old stability chambers began failing unexpectedly during ongoing long-term studies. With no clear plan to decommission, replace, or divert samples, the company scrambled to move materials to external partners to keep the research valid. Delays were only narrowly avoided.
High-profile recalls underscore the risks of poor temperature control. For example, in 2021 cold chain lapses triggered insulin recalls when finished samples were stored below freezing, damaging both the formulation and the delivery (7). Similarly, in April 2025, a nationwide recall of a specific lot of the top-selling GLP-1 agonist (semaglutide) for weight management occurred after cartons were distributed without proper refrigeration, putting patients at risk due to compromised potency (8). While these specific recalls involve storage of the final product, the same temperature controls are critical during production: in-process bulk solutions, intermediates, or stability samples all depend on precise storage conditions. A lapse at this stage can degrade product quality long before distribution, demonstrating how overlooked temperature controls directly threaten drug integrity and patient safety.
A modelling study found that drug shortage frequencies could be cut by adding backup suppliers and recovery capacity early in planning (9). The lesson is simple: build your disaster recovery plan before you need it. For storage, this can mean secondary or tertiary sites, validated backup capacity, routine disaster drills, and local agreements for emergency equipment rental or transport. Few things are as costly as a delayed recovery plan.
Best practice tip: Build robust disaster recovery and continuity plans long before they’re needed. Establish pre-contracted disaster recovery supplier relationships to guarantee storage space availability and ensure speed of relocation when the unexpected occurs.
Data is part of viability
Storing a sample is only the start; proving its integrity requires reliable data. When audits come, inspectors expect documented proof that conditions were within spec, that consent forms were valid, and that chain-of-custody records are traceable.
Today, around 80% of pharma cold chain shipments require monitoring in real time using internet of things (IoT) and smart sensors (10). This technology is rapidly becoming standard. But digital traceability must run deeper: consent records, temperature logs, deviation reports, and corrective actions all need to connect to each stored unit.
Modern SOPs should define how data is captured, where it is stored, who verifies it, and how it can be produced for audit. For large, multi-site organizations, this also means integrating different data streams — internal lab records, vendor reports, logistics trackers — under a single oversight plan. In a tight regulatory environment, good data can mean the difference between an approved study and an expensive repeat.
How to scale sustainably and when to outsource
When R&D pipelines are small, internal storage often makes sense: it keeps teams close to samples and allows quick access. But as companies grow (expanding study numbers, adding sites, or partnering with multiple CROs and CDMOs), the scale of the challenge changes. New products might need unique storage conditions. Old infrastructure may not flex easily. Real estate or utility limits can become real bottlenecks.
It is no surprise that globally nearly 50% of R&D services are now outsourced, with outsourced cold chain and storage logistics partners representing a fast-growing share of the sample storage market (11). Many companies choose hybrid approaches: some samples stay in-house; others move to validated off-site capacity with experts focused only on storage quality and continuity.
One large pharmaceutical company discovered that its storage model had become fragmented over time. Samples were spread across multiple sites and teams operated in silos, creating duplication and risk. By consolidating oversight and outsourcing part of its storage capacity, the company reduced hidden costs, improved compliance visibility, and freed its scientists to focus on core research rather than freezer alarms.
A practical next step: do the cost–benefit math
Cold chain spending is projected to grow by 9–10% annually through 2030 (6). Yet many operations teams still treat storage and logistics as static cost centers, not as risks and opportunities to optimize. The reality is that failing to modernize old chambers, pushing capacity limits, or missing compliance upgrades can cost far more than expected.
One practical action: run a simple ROI test. Compare the real cost of internal storage (equipment, power, real estate, staffing, maintenance, compliance) with the cost of working with an expert partner. Include hidden costs: downtime, failures, lost samples, emergency shipments. Some companies even use free online calculators to plug in key figures like sample volumes, study durations, and transport frequencies to test if the current model still makes sense.
Smart companies revisit this exercise regularly, not just when a crisis hits. For many, the answer will be a mix; insource what you do best, outsource where you need scale, security, or specialist expertise.
Conclusion
Every sample represents more than material. It represents time, patient trust, and the future of innovation. Companies that treat storage and logistics as afterthoughts risk undermining their own progress. By planning for sustainability, scalability, and resilience now — and by using data and trusted partners, such as Astoriom, wisely — organizations can protect research investments and maintain their path to discovery.
References and notes
- Air Cargo News. Failures in temperature-controlled logistics cost biopharma industry billions. [Internet]. Air Cargo News; 2019 Jul 19 [cited 2025 Jul 17]. Available from: https://www.aircargonews.net/failures-in-temperature-controlled-logistics-cost-biopharma-industry-billions/1024281.article
- Linder, J. Supply Chain In The Pharmaceutical Industry Statistics [Internet]. Gitnux; 2025 Apr 29 [cited 2025 Jul 17]. Available from: https://gitnux.org/supply-chain-in-the-pharmaceutical-industry-statistics/
- FDA. ICH Q1A(R2) Stability Testing of New Drug Substances and Products [Internet]. 2003 [cited 2025 Jul 17]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q1ar2-stability-testing-new-drug-substances-and-products
- FDA. Guideline for Industry. Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products [Internet]. 1996 [cited 2025 Jul 17]. Available from: https://www.fda.gov/media/71441/download
- Leucine. Most Common FDA Form 483 Observations in Equipment Qualification (2022–2025) [Internet]. Leucine.io; 2025 [cited 2025 Jul 17]. Available from: https://www.leucine.io/fda-483-analysis/top-fda-form-483-observations-in-equipment-qualification-2022-2024-insights-and-escalation-risks
- Grand View Research. Cold chain Market Trends & Insights [Internet]. 2024 [cited 2025 Jul 17]. Available from: https://www.grandviewresearch.com/industry-analysis/cold-chain-market
- Global Reach Health. NovoNordisk Recalls Samples of Insulin Products [Internet]. 2021 May 7 [cited 2025 Jul 17]. Available from: https://www.globalreachhealth.com/novonordisk-recalls-samples-of-insulin-products/
- Musick, H. FDA Issues Class II Recall for Wegovy. Pharmacy Learning Network, HMP Global Learning Network [Internet]. 2025 May 1 [cited 2025 Jul 17]. Available from: https://www.hmpgloballearningnetwork.com/site/pln/news/fda-issues-class-ii-recall-wegovy
- arXiv. Pharmaceutical Supply Chain Reliability and Effects on Drug Shortages [Internet]. 2021 [cited 2025 Jul 17]. Available from: https://arxiv.org/pdf/2107.09167
- UPS Healthcare. UPS Healthcare Invests Over €20M in EU Cold Chain Fleet [Internet]. 2024 Jul 24 [cited 2025 Jul 17]. Available from: https://www.ups.com/gb/en/healthcare/news/press-releases/ups-healthcare-invests-in-eu-cold-chain-fleet
- Credence Research. U.S. Pharma R&D Outsourcing Market Overview [Internet]. 2023 Dec 19 [cited 2025 July 17], Available from: https://www.credenceresearch.com/report/u-s-pharma-rd-outsourcing-market
